Pressmeddelande

Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company

Aktiespararna (The Swedish Shareholders’ Association) is an organization for private Investors in equities and funds. Analysguiden is Aktiespararna’s commissioned research service, where investors can access analyses of the listed companies the association covers. The initial report will be available on Aktiespararna’s website: https://www.aktiespararna.se/analyser

Aktiespararna regularly hosts investor events. On June 9 at 16:00 CEST, Sprint Bioscience’s CEO Johan Emilsson will present the company at “Aktiedagarna in Stockholm” at the Birger Jarl Conference. https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-68173

The investor event will be live-streamed via the link below. No registration is required to watch the broadcast. https://invitepeople.com/public/events/fa647c6285/pages/ea19175b1c

Please note that the main language of the event is Swedish.

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.